Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Liver Diseases

Free Subscription 15.12.2025 1 Am J Gastroenterol 2 Biochem Biophys Res Commun 6 BMC Cancer 5 BMC Gastroenterol 2 Clin Res Hepatol Gastroenterol 4 Dig Dis Sci 3 Endoscopy 1 Gut 2 Hepatology 1 Indian J Gastroenterol 1 Int J Cancer 1 J Gastroenterol Hepatol 4 J Hepatol 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Imaging Cancer 3 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. RODRIGUEZ N, Katzenstein C, Alpert L, Sigel K, et al
   Evaluating the 2023 EASL guidelines for intrahepatic cholestasis of pregnancy: risk stratification and outcomes in over 4,000 U.S. patients.
   Am J Gastroenterol. 2025 Nov 24. doi: 10.14309/ajg.0000000000003866.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. SINGH MM, Shahi A, Chaturvedi CP, Rajak S, et al
   Inhibition of histone-lysine N-methyltransferase G9a exacerbates alcoholic steatohepatitis (ASH) in mice.
   Biochem Biophys Res Commun. 2025;794:153072.
   PubMed         Abstract available
   
   
3. SERAMUR ME, Sink S, Reeves TE, Solberg Woods LC, et al
   Pharmacological inhibition of G protein-coupled receptor kinase 5 decreases high-fat diet-induced hepatic steatosis in mice.
   Biochem Biophys Res Commun. 2025;795:153078.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. LI J, Huo S, Ma J, Ren L, et al
   Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma.
   BMC Cancer. 2025;25:1855.
   PubMed         Abstract available
   
   
5. YU H, Wu J, Gao L
   Elevated expression of CK19, Ki67, and beta-Catenin as prognostic biomarkers in hepatocellular carcinoma.
   BMC Cancer. 2025 Dec 12. doi: 10.1186/s12885-025-15429.
   PubMed         Abstract available
   
   
6. TU K, Dou C, Zheng X, Li C, et al
   Retraction Note: Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
   BMC Cancer. 2025;25:1867.
   PubMed        
   
   
7. ZHAO P, Li J, Xu Y, Qu J, et al
   Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.
   BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15408.
   PubMed         Abstract available
   
   
8. CHEN L, Xu J, Li J, Ji K, et al
   The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.
   BMC Cancer. 2025 Dec 10. doi: 10.1186/s12885-025-15442.
   PubMed         Abstract available
   
   
9. FU J, Peng W, Jiang J, Deng T, et al
   Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: a meta-analysis.
   BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15310.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

10. PHUKAN C, Talukdar AJ, Dutta S, Saha S, et al
    Novel urinary biomarkers to differentiate AKI etiologies and predict mortality in decompensated cirrhosis patients: a prospective cohort study.
    BMC Gastroenterol. 2025 Dec 7. doi: 10.1186/s12876-025-04462.
    PubMed         Abstract available
    
    
11. JIANG D, Liu Z, Wang K, Qian Y, et al
    Integrated ultrasound radiomics and clinical data to predict PD-1 blockade efficacy in unresectable hepatocellular carcinoma.
    BMC Gastroenterol. 2025 Dec 7. doi: 10.1186/s12876-025-04512.
    PubMed         Abstract available
    
    
12. NG M, Bardhi O, Lai K, Koo E, et al
    Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma.
    BMC Gastroenterol. 2025 Dec 9. doi: 10.1186/s12876-025-04538.
    PubMed         Abstract available
    
    
13. YANG X, Xie D, Du Y, Zhang D, et al
    Analysis of risk factors and correlation between the degree of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis.
    BMC Gastroenterol. 2025 Dec 10. doi: 10.1186/s12876-025-04504.
    PubMed         Abstract available
    
    
14. YASER S, Yaser H, Mohammed HE, Nasser M, et al
    Efficacy of pharmacotherapies on pediatric patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis.
    BMC Gastroenterol. 2025;25:853.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

15. MARYAM A, Naghshzan A, Mahmood H, Mohsen D, et al
    Cirrhotic Cardiomyopathy in Children: A Comprehensive Assessment Using ECG, Echocardiography, and NT-Pro-BNP.
    Clin Res Hepatol Gastroenterol. 2025 Oct 28:102721.
    PubMed         Abstract available
    
    
16. CORSI O, Jara C, Fernandez M, Pastore A, et al
    Is cholecystectomy a real risk factor for Metabolic dysfunction-associated steatotic liver disease (MASLD)? A longitudinal cohort study from a population with a high burden of gallbladder diseases.
    Clin Res Hepatol Gastroenterol. 2025;49:102732.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

17. AMEYAW PA, Boateng S, Issaka Y, Ackah ES, et al
    Outcomes of Acute Pancreatitis in Lean Versus Non-lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: A Nationwide Analysis.
    Dig Dis Sci. 2025 Jul 26. doi: 10.1007/s10620-025-09245.
    PubMed         Abstract available
    
    
18. ZHANG J, Ren Y
    Lean MASLD Cirrhosis and Mortality: Considerations for Liver Transplant Candidate Evaluation.
    Dig Dis Sci. 2025 Dec 11. doi: 10.1007/s10620-025-09601.
    PubMed        
    
    
19. CHEN X, Wang L, Yan Y, Qin J, et al
    Colorectal Metastasis of Hepatocellular Carcinoma Mimicking Yamada Type III Polyp Leading to Gastrointestinal Bleeding.
    Dig Dis Sci. 2025 Dec 8. doi: 10.1007/s10620-025-09579.
    PubMed        
    
    
20. VONGSAVATH T, Manne V, Sakae C, Saab S, et al
    Management of Refractory Hepatic Encephalopathy.
    Dig Dis Sci. 2025 Dec 5. doi: 10.1007/s10620-025-09591.
    PubMed         Abstract available
    
    

    
    Endoscopy

21. HATTORI N, Ogura T, Nakamura J, Kanadani T, et al
    Radial laser ablation under cholangioscopic guidance for a tight intrahepatic bile duct stricture caused by primary sclerosing cholangitis.
    Endoscopy. 2025;57.
    PubMed        
    
    
22. OKUNO N, Hara K, Haba S, Kuwahara T, et al
    Endoscopic ultrasound-guided choledochoduodenojejunostomy via afferent limb: a novel approach for hepaticojejunostomy stricture.
    Endoscopy. 2025;57.
    PubMed        
    
    
23. LI J, Zhou Y, Wang J, Feng J, et al
    Endoscopic ultrasound-guided portal vein marking facilitates transjugular intrahepatic portosystemic shunt for portal cavernoma.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Gut

24. LUO J, Hu M, Feng T, Zhang L, et al
    Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies.
    Gut. 2025;75:131-146.
    PubMed         Abstract available
    
    

    
    Hepatology

25. JI J, Chen Z, He W, Chen Y, et al
    CXCR6 defines a distinct resident state in gammadelta T cells for protecting from liver cirrhosis.
    Hepatology. 2025 Dec 11. doi: 10.1097/HEP.0000000000001643.
    PubMed         Abstract available
    
    
26. XUN Z, Wang H, Xuan Z, Xiong K, et al
    Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.
    Hepatology. 2025 Dec 10. doi: 10.1097/HEP.0000000000001641.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

27. VADLAPUDI SS, Poddar U
    Non-hepatoblastoma pediatric liver tumors: Unravelling of a lesser-known entity.
    Indian J Gastroenterol. 2025 Dec 10. doi: 10.1007/s12664-025-01903.
    PubMed        
    
    

    
    Int J Cancer

28. CHAI X, Chen J, Zhao Y, Chu W, et al
    G9a epigenetically suppresses CXCL10 expression and inhibits anti-tumor immunity in hepatocellular carcinoma.
    Int J Cancer. 2025 Dec 9. doi: 10.1002/ijc.70284.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

29. DIRJAYANTO VJ, Yiu DSM, Chen R, Fan KH, et al
    Nutrition in Hepatocellular Carcinoma: Pathophysiological Insights, Impact, and Implications for Clinical Practice.
    J Gastroenterol Hepatol. 2025 Dec 12. doi: 10.1111/jgh.70186.
    PubMed         Abstract available
    
    

    
    J Hepatol

30. ENGELMANN C
    Decoding the metabolic dialogue between hepatocytes and macrophages driving liver regeneration.
    J Hepatol. 2025 Dec 4:S0168-8278(25)02629-7. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
31. HSU CL, Su YY, Ou DL, Hsu C, et al
    Reply to: "Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration".
    J Hepatol. 2025 Dec 8:S0168-8278(25)02713-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
32. KEITEL V, Kreissl MC, Goetze T, Droge C, et al
    CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.
    J Hepatol. 2025 Dec 8:S0168-8278(25)02711-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
33. ZHANG Z, Fang T, Wu P, Sun B, et al
    Hepatocyte-specific ablation of LONP1 disrupts liver glucose homeostasis in mice.
    J Hepatol. 2025 Dec 8:S0168-8278(25)02712-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    PLoS One

34. HORI T, Aihara KI, Kawano Y, Watanabe T, et al
    Fibrosis-4 and 3 indices are independently associated with annual hemoglobin decline in individuals with metabolic disorders: A hospital-based retrospective cohort study.
    PLoS One. 2025;20:e0338372.
    PubMed         Abstract available
    
    
35. ZHENG S, Yu X, Wang X, Ma Y, et al
    DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS.
    PLoS One. 2025;20:e0338091.
    PubMed         Abstract available
    
    
36. FUHRMANN V, Tyczynski B, Perez Ruiz de Garibay A, Bingold TM, et al
    The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS).
    PLoS One. 2025;20:e0318917.
    PubMed         Abstract available
    
    
37. PENG Z, Shen L, Wang Y, Chen B, et al
    Comparative effectiveness of adjuvant treatment for hepatocellular carcinoma with high risk of recurrence: A systematic review and network meta-analysis.
    PLoS One. 2025;20:e0335457.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. QIN Q, Chen W, King CD, Kumar SP, et al
    Identification of an IRF-ZBP1-caspase-8-NINJ1 axis in driving PANoptosis and pathology during alcohol-associated liver disease.
    Proc Natl Acad Sci U S A. 2025;122:e2525296122.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

39. WANG Y, Zhu Z, Zhu M, Wu S, et al
    Arterial-Washout Temporal Profiling in CEUS LI-RADS: A Diagnostic Algorithm for Reducing Hepatocellular Carcinoma Misclassification.
    Radiol Imaging Cancer. 2026;8:e250259.
    PubMed         Abstract available
    
    

    
    Transplant Proc

40. HILL AL, Kiani AZ, Vachharajani N, Martens GR, et al
    ABO-Incompatible Liver Transplantation Is an Underused Resource for Improving Access to Liver Transplantation.
    Transplant Proc. 2025 Nov 6:S0041-1345(25)00526.
    PubMed         Abstract available
    
    
41. SOBNACH S, Kotze U, Kim I, Spearman CW, et al
    From Metro Ticket to a Cape-to-Khartoum Pass: Reimagining Liver Transplantation Criteria for HCC in Sub-Saharan Africa.
    Transplant Proc. 2025 Nov 1:S0041-1345(25)00524.
    PubMed         Abstract available
    
    
42. CHENG SM, Weng LC, Lee WC, Chen LT, et al
    The Correlation of Hemodynamic Changes and Early Allograft Function Following Liver Transplantation.
    Transplant Proc. 2025 Oct 31:S0041-1345(25)00543.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.